OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
PEARL Study Protocol: a Real-World Study of Fremanezumab Effectiveness in Patients with Chronic or Episodic Migraine
Messoud Ashina, Faisal Mohammad Amin, Pinar Kokturk, et al.
Pain Management (2021) Vol. 11, Iss. 6, pp. 647-654
Open Access | Times Cited: 15
Messoud Ashina, Faisal Mohammad Amin, Pinar Kokturk, et al.
Pain Management (2021) Vol. 11, Iss. 6, pp. 647-654
Open Access | Times Cited: 15
Showing 15 citing articles:
Machine‐learning‐based approach for predicting response to anti‐calcitonin gene‐related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study
Alicia González‐Martínez, Josué Pagán, Ancor Sanz‐García, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 10, pp. 3102-3111
Closed Access | Times Cited: 30
Alicia González‐Martínez, Josué Pagán, Ancor Sanz‐García, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 10, pp. 3102-3111
Closed Access | Times Cited: 30
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
Fred Cohen, Hsiangkuo Yuan, Stephen D. Silberstein
BioDrugs (2022) Vol. 36, Iss. 3, pp. 341-358
Open Access | Times Cited: 29
Fred Cohen, Hsiangkuo Yuan, Stephen D. Silberstein
BioDrugs (2022) Vol. 36, Iss. 3, pp. 341-358
Open Access | Times Cited: 29
Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications
Aynur Özge, Betül Baykan, Şebnem Bıçakçı, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Aynur Özge, Betül Baykan, Şebnem Bıçakçı, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
Valeria Caponnetto, Antonio Russo, Marcello Silvestro, et al.
CNS Drugs (2023) Vol. 37, Iss. 12, pp. 1069-1080
Open Access | Times Cited: 7
Valeria Caponnetto, Antonio Russo, Marcello Silvestro, et al.
CNS Drugs (2023) Vol. 37, Iss. 12, pp. 1069-1080
Open Access | Times Cited: 7
The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness
Cristina Tassorelli, Piero Barbanti, Cinzia Finocchi, et al.
Neurological Sciences (2024) Vol. 45, Iss. 5, pp. 2353-2363
Open Access | Times Cited: 2
Cristina Tassorelli, Piero Barbanti, Cinzia Finocchi, et al.
Neurological Sciences (2024) Vol. 45, Iss. 5, pp. 2353-2363
Open Access | Times Cited: 2
The effect of bright light therapy in migraine patients with sleep disturbance: A prospective, observational cohort study protocol
Tsung-Hsing Lin, Cheng‐Chia Yang, Shih‐Yu Lee, et al.
Frontiers in Aging Neuroscience (2023) Vol. 14
Open Access | Times Cited: 6
Tsung-Hsing Lin, Cheng‐Chia Yang, Shih‐Yu Lee, et al.
Frontiers in Aging Neuroscience (2023) Vol. 14
Open Access | Times Cited: 6
Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
Christopher Kjær Cullum, Basit Ali Chaudhry, Thien Phu, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 6
Christopher Kjær Cullum, Basit Ali Chaudhry, Thien Phu, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 6
Update of Gepants in the Treatment of Chronic Migraine
Soohyun Cho, Byung‐Kun Kim
Current Pain and Headache Reports (2023) Vol. 27, Iss. 10, pp. 561-569
Closed Access | Times Cited: 6
Soohyun Cho, Byung‐Kun Kim
Current Pain and Headache Reports (2023) Vol. 27, Iss. 10, pp. 561-569
Closed Access | Times Cited: 6
Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study
Alicia González‐Martínez, Ancor Sanz‐García, David García‐Azorín, et al.
Pain Medicine (2023) Vol. 25, Iss. 3, pp. 194-202
Closed Access | Times Cited: 6
Alicia González‐Martínez, Ancor Sanz‐García, David García‐Azorín, et al.
Pain Medicine (2023) Vol. 25, Iss. 3, pp. 194-202
Closed Access | Times Cited: 6
Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study
Messoud Ashina, Dimos D. Mitsikostas, Faisal Mohammad Amin, et al.
Cephalalgia (2023) Vol. 43, Iss. 11
Open Access | Times Cited: 4
Messoud Ashina, Dimos D. Mitsikostas, Faisal Mohammad Amin, et al.
Cephalalgia (2023) Vol. 43, Iss. 11
Open Access | Times Cited: 4
The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
Л А Добрынина, M A Afanasev, А. В. Белопасова, et al.
Annals of Clinical and Experimental Neurology (2023) Vol. 17, Iss. 2, pp. 22-27
Open Access | Times Cited: 1
Л А Добрынина, M A Afanasev, А. В. Белопасова, et al.
Annals of Clinical and Experimental Neurology (2023) Vol. 17, Iss. 2, pp. 22-27
Open Access | Times Cited: 1
Recomendaciones de la Asociación Colombiana de Neurología para el uso de anticuerpos monoclonales antiCGRP en la profilaxis de migraña
Oscar Enrique Pradilla-Vesga, José David Martinez, Mauricio Rueda-Sánchez, et al.
Acta neurológica colombiana (2022) Vol. 38, Iss. 1 Supl 1, pp. 1-22
Open Access | Times Cited: 1
Oscar Enrique Pradilla-Vesga, José David Martinez, Mauricio Rueda-Sánchez, et al.
Acta neurológica colombiana (2022) Vol. 38, Iss. 1 Supl 1, pp. 1-22
Open Access | Times Cited: 1
Multicentre Real-World Case-Control Study of Effectiveness, Tolerability, and Anti-Calcitonin Gene-Related Peptide Response Predictors in the Elderly
Alicia González‐Martínez, Ancor Sanz‐García, Jaime Samuel Rodríguez‐Vico, et al.
EMJ Neurology (2023), pp. 49-51
Open Access
Alicia González‐Martínez, Ancor Sanz‐García, Jaime Samuel Rodríguez‐Vico, et al.
EMJ Neurology (2023), pp. 49-51
Open Access
Tratamiento preventivo de la migraña con fremanezumab subcutáneo
R. Belvís, Noemí Morollón
Kranion (2022) Vol. 16, Iss. 4
Open Access
R. Belvís, Noemí Morollón
Kranion (2022) Vol. 16, Iss. 4
Open Access
